Central Retinal Vein Occlusion Treatment with Aflibercept-ayyh

Primary Treatment Indication

The American Academy of Ophthalmology recommends dense peripheral panretinal photocoagulation as the primary treatment for retinal neovascularization following central retinal vein occlusion, but anti-VEGF agents are used in an adjunctive manner when complete PRP is insufficient to control angiogenesis 1, 3
Anti-VEGF agents reduce the severity of neovascularization and lower the risk of ocular angiogenesis in patients with central retinal vein occlusion 3, 4
Initial treatment with an anti-VEGF agent provides immediate benefit and may improve the ability to deliver complete laser treatment in patients with central retinal vein occlusion 1, 5

Anti-VEGF agents are effective at limiting neovascularization associated with retinal vein occlusions, with a significant reduction in the risk of neovascular complications 3, 6

The American Academy of Ophthalmology recognizes biosimilars of aflibercept, including Pavblu, as appropriate alternatives in treatment guidelines for retinal vein occlusion 1, 3
Current guidelines state that three anti-VEGF agents (ranibizumab and aflibercept are FDA-approved) are used routinely for RVO treatment, and biosimilars are considered therapeutically equivalent for approved indications 1, 2

The patient should continue to be monitored for neovascular complications, and anti-VEGF therapy should be initiated as adjunctive treatment to prevent progression to neovascular glaucoma 1, 2
The goal of treatment is to prevent progression to iris neovascularization and neovascular glaucoma, and anti-VEGF treatment provides immediate benefit while PRP effects develop 1, 5

Intravitreal anti-VEGF injections have a favorable risk-to-benefit profile with minimal systemic risks, and severe adverse effects are uncommon, including endophthalmitis, retinal detachment, and elevated IOP 7